Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

XDx

- PMLiVE

Novartis scores promising phase 3 MS study

Takes fight to Roche’s blockbuster ocrevus

- PMLiVE

Novartis chooses internal replacement for US pharma president role

Victor Bulto to lead US pharma business

Novartis day

Senators attack Novartis over ‘unconscionable’ handling of Zolgensma data

Ask FDA to hold the company ‘accountable’

Lucid Group supercharges its client services team with four spellbinding new hires

Lucid Group makes four magical additions to its client services team!Annabel Lloyd joins Vivid as an account director. With experience in a variety of therapy areas from immunology, oncology, CVD...

Lucid Group Communications Limited

- PMLiVE

ICER closely monitoring FDA’s Zolgensma investigation

Could affect initial cost assessment

Novartis day

Novartis defends Zolgensma as FDA investigates ‘data manipulation’

Gene therapy will remain on the market

Novartis day

Blow for Entresto in latest heart failure trial

Aim of being first in HFpEF in serious doubt

- PMLiVE

AZ and Novartis ‘most exposed’ to Senate pricing proposals

Most expensive therapies will be penalised

Novartis day

Novartis raises 2019 guidance as new products gather speed

Cosentyx leads the way with 25% growth

- PMLiVE

FDA starts speedy review of Novartis’ sickle cell antibody

Among several $1bn+ late-stage drugs in company's pipeline

Bluedog is bursting with new creative and digital talent

Bluedog, a Lucid Group company, welcomes four spellbinding new additions to its team.With a strong background in animation, Rachel Sparks joins Bluedog as a motion designer. Having previously worked in...

Lucid Group Communications Limited

- PMLiVE

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Latest BACE inhibitor to run into trouble

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links